Conclusion Semaglutide reduces the risk of AF, sinus node dysfunction, acute myocardial infarction, and angina pectoris in patients with overweight or obesity
151 However, clinical trials to test its effects in patients have only recently started, and published results of CR interventions are restricted to small pilot studies or case reports, 75, 76, 77, 152, 153, 154, 155, 156, 157, 158, 159 which we summarize in Table 2
We start low, raise your dose gradually, and watch how you respond, adjusting before small problems become reasons to quit
Your prescribing provider monitors for thyroid changes, pancreatitis symptoms, kidney function, and cardiovascular markers during long-term use, as recommended by clinical guidelines